Symbol | Exchange | Currency | ||
---|---|---|---|---|
OMED | NASDAQ | USD | Real-time | |
O0M | Berlin | EUR | Delayed | |
O0M | Stuttgart | EUR | Delayed |
Type | 5 mins | 15 mins | Hourly | Daily | Monthly |
---|---|---|---|---|---|
Moving Averages | Buy | Neutral | Sell | Strong Sell | Sell |
Technical Indicators | Strong Buy | Strong Buy | Strong Sell | Sell | Strong Sell |
Summary | Strong Buy | Buy | Strong Sell | Strong Sell | Strong Sell |
Filter Table By:
Pattern | Timeframe | Reliability | Candles Ago | Candle Time | |
---|---|---|---|---|---|
Emerging Patterns | |||||
Engulfing Bearish | 1W | Current | |||
Completed Patterns | |||||
Bullish Engulfing | 1M | 1 | Mar 18 | ||
Falling Three Methods | 1D | 1 | Apr 18, 2018 | ||
Engulfing Bearish | 1D | 2 | Apr 17, 2018 |
Exchange | Last | Bid | Ask | Volume | Change % | Currency | Time | ||
---|---|---|---|---|---|---|---|---|---|
NASDAQ | 3.08 | 3.00 | 4.20 | 54,344 | +1.99% | USD | 15:59:59 | ||
Berlin | 2.410 | 0.000 | 0.000 | 0 | -5.12% | EUR | 12:30:00 | ||
Stuttgart | 2.410 | 0.000 | 0.000 | 0 | -2.43% | EUR | 13:49:00 |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
---|---|---|---|---|---|---|---|---|---|
Apple | 172.80 | 175.39 | 172.66 | -5.04 | -2.83% | 34.81M | 15:59:59 | ||
Tata Consultancy | 3,191.15 | 3,217.20 | 3,165.75 | +32.05 | +1.01% | 2.41M | 6:29:11 | ||
Amazon.com | 1,556.91 | 1,568.52 | 1,539.06 | +29.07 | +1.90% | 6.52M | 15:59:59 | ||
IBM | 147.70 | 149.21 | 146.62 | -1.09 | -0.73% | 8.09M | 15:59:59 | ||
Alibaba | 181.39 | 183.63 | 179.52 | -1.29 | -0.71% | 11.99M | 15:59:59 | ||
168.10 | 168.33 | 165.20 | +1.74 | +1.05% | 22.23M | 15:59:59 | |||
Philip Morris | 85.64 | 94.26 | 83.50 | -15.80 | -15.58% | 45.57M | 15:59:59 | ||
Sri Rejeki Isman | 364 | 372 | 356 | +8 | +2.25% | 404.51M | 22:47:00 | ||
Tesla | 300.08 | 301.01 | 288.55 | +6.73 | +2.29% | 6.09M | 15:59:59 | ||
Netflix | 332.70 | 335.31 | 326.77 | -1.82 | -0.54% | 8.44M | 15:59:59 |
OncoMed Pharmaceuticals, Inc. (OncoMed) is a clinical-stage biopharmaceutical company. The Company focuses on discovering and developing therapeutics that address the fundamental biology driving cancer's growth, resistance, recurrence and metastasis. The Company's therapeutic candidates and preclinical programs include Demcizumab (Anti-DLL4, OMP-21M18), Tarextumab (Anti-Notch2/3, OMP-59R5), Vantictumab (anti-Fzd7, OMP-18R5), Ipafricept (Fzd8-Fc, OMP-54F28), Brontictuzumab (Anti-Notch1, OMP-52M51), Navicixizumab (Anti-DLL4/VEGF Bispecific, OMP-305B83), Anti-RSPO3 (OMP-131R10), Anti-TIGIT (OMP-313M32) and GITRL-Fc trimer (OMP-336B11). Demcizumab is a humanized monoclonal antibody that inhibits Delta-like Ligand 4 (DLL4) in the Notch signaling pathway. Tarextumab is a human monoclonal antibody that binds to both the Notch2 and Notch3 receptors.
Read MoreBrokers | Regulation | Minimum Deposit | |
---|---|---|---|
![]() |
U.S. Commodity Futures Trading Commission (United States) | $250 | Start Trading |
![]() |
National Futures Association (United States), U.S. Commodity Futures Trading Commission (United States), The Financial Conduct Authority (United Kingdom), Australian Securities and Investments Commission (Australia), Financial Industry Regulatory Authority (United States), Investment Industry Regulatory Organization of Canada (Canada), Securities and Exchange Board of India (India), Securities and Exchange Commission (United States), The Securities and Futures Commission (Hong Kong), Securities Investor Protection Corporation (United States) | $10000 | Start Trading |
![]() |
U.S. Commodity Futures Trading Commission (United States) | Start Trading |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review